41st Annual J.P. Morgan Healthcare Conference
mAbs, Gene Therapy and mRNA fueling our growth
Monoclonal
Antibodies
Cell & Gene
Therapy
R REPLIGEN
~$150B
Market 2021
Growing at
>10% annually
>$5B
Market 2021
Growing at
>25% annually
>140
U.S. FDA
Approvals
incl.
26 Biosimilars
14
U.S. FDA
Approvals
incl.
9 Cell, 5 GT
>800
Phase I-III
>1,500
Active clinical trials
>500
Phase I-III
>1,100
Active clinical trials
New approvals
and growing
biosimilars
pipeline
Emerging
opportunities
beyond COVID
Data sources: $s Company filings/guidance; Approvals: U.S. FDA website; Industry articles incl. www.genengnews.com/a-lists/top-11-best-selling-covid-19-vaccines-and-drugs-of-h1-2021/mAb approvals:
Antibody therapeutics approved or in regulatory review in the EU or US - The Antibody Society/; PHrMA report https://phrma.org/-/media/Project/PhRMA/PhRMA-Org/PhRMA-Org/PDF/A-C/MID-cell-and-
gene-therapy-2020.pdf; Repligen internal mAbs tracker; Market research reports (Research and Markets, Allied Market Research, Brandessence Research, Fortune Business Highlights, Qualiket Research..
Candidates C>: 2)Cell & Gene Therapy reports: American Society of Gene + Cell Therapy: Q2 2022 Cell, Gene & RNA Therapy Trials C>: BioCentury
8View entire presentation